vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $124.7M, roughly 2.0× SMITH & WESSON BRANDS, INC.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 1.5%, a 9.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -3.9%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $16.3M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -4.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
ANIP vs SWBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $124.7M |
| Net Profit | $27.5M | $1.9M |
| Gross Margin | — | 24.3% |
| Operating Margin | 14.1% | 3.3% |
| Net Margin | 11.1% | 1.5% |
| Revenue YoY | 29.6% | -3.9% |
| Net Profit YoY | 367.5% | -53.6% |
| EPS (diluted) | $1.14 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $124.7M | ||
| Q3 25 | $227.8M | $85.1M | ||
| Q2 25 | $211.4M | $140.8M | ||
| Q1 25 | $197.1M | $115.9M | ||
| Q4 24 | $190.6M | $129.7M | ||
| Q3 24 | $148.3M | $88.3M | ||
| Q2 24 | $138.0M | $159.1M | ||
| Q1 24 | $137.4M | $137.5M |
| Q4 25 | $27.5M | $1.9M | ||
| Q3 25 | $26.6M | $-3.4M | ||
| Q2 25 | $8.5M | $8.6M | ||
| Q1 25 | $15.7M | $2.1M | ||
| Q4 24 | $-10.3M | $4.5M | ||
| Q3 24 | $-24.2M | $-1.9M | ||
| Q2 24 | $-2.3M | $27.9M | ||
| Q1 24 | $18.2M | $7.9M |
| Q4 25 | — | 24.3% | ||
| Q3 25 | — | 25.9% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 24.1% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | 14.1% | 3.3% | ||
| Q3 25 | 15.9% | -3.5% | ||
| Q2 25 | 6.6% | 9.3% | ||
| Q1 25 | 13.3% | 4.1% | ||
| Q4 24 | -2.3% | 5.8% | ||
| Q3 24 | -13.8% | -1.7% | ||
| Q2 24 | 3.7% | 17.4% | ||
| Q1 24 | 14.8% | 8.2% |
| Q4 25 | 11.1% | 1.5% | ||
| Q3 25 | 11.7% | -4.0% | ||
| Q2 25 | 4.0% | 6.1% | ||
| Q1 25 | 8.0% | 1.8% | ||
| Q4 24 | -5.4% | 3.5% | ||
| Q3 24 | -16.3% | -2.1% | ||
| Q2 24 | -1.7% | 17.5% | ||
| Q1 24 | 13.2% | 5.7% |
| Q4 25 | $1.14 | $0.04 | ||
| Q3 25 | $1.13 | $-0.08 | ||
| Q2 25 | $0.36 | $0.19 | ||
| Q1 25 | $0.69 | $0.05 | ||
| Q4 24 | $-0.45 | $0.10 | ||
| Q3 24 | $-1.27 | $-0.04 | ||
| Q2 24 | $-0.14 | $0.60 | ||
| Q1 24 | $0.82 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $363.2M |
| Total Assets | $1.4B | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $22.4M | ||
| Q3 25 | $262.6M | $18.0M | ||
| Q2 25 | $217.8M | $25.2M | ||
| Q1 25 | $149.8M | $26.7M | ||
| Q4 24 | $144.9M | $39.1M | ||
| Q3 24 | $145.0M | $35.5M | ||
| Q2 24 | $240.1M | $60.8M | ||
| Q1 24 | $228.6M | $47.4M |
| Q4 25 | $540.7M | $363.2M | ||
| Q3 25 | $505.8M | $364.4M | ||
| Q2 25 | $436.8M | $372.5M | ||
| Q1 25 | $418.6M | $366.9M | ||
| Q4 24 | $403.7M | $371.5M | ||
| Q3 24 | $405.9M | $380.0M | ||
| Q2 24 | $455.8M | $399.9M | ||
| Q1 24 | $452.0M | $376.4M |
| Q4 25 | $1.4B | $548.6M | ||
| Q3 25 | $1.4B | $554.6M | ||
| Q2 25 | $1.3B | $559.6M | ||
| Q1 25 | $1.3B | $578.9M | ||
| Q4 24 | $1.3B | $587.4M | ||
| Q3 24 | $1.3B | $571.3M | ||
| Q2 24 | $920.8M | $577.4M | ||
| Q1 24 | $914.5M | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $27.3M |
| Free Cash FlowOCF − Capex | $29.1M | $16.3M |
| FCF MarginFCF / Revenue | 11.8% | 13.1% |
| Capex IntensityCapex / Revenue | 0.5% | 8.8% |
| Cash ConversionOCF / Net Profit | 1.10× | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $27.3M | ||
| Q3 25 | $44.1M | $-8.1M | ||
| Q2 25 | $75.8M | $40.8M | ||
| Q1 25 | $35.0M | $-9.8M | ||
| Q4 24 | $15.9M | $-7.4M | ||
| Q3 24 | $12.5M | $-30.8M | ||
| Q2 24 | $17.4M | $43.7M | ||
| Q1 24 | $18.3M | $25.2M |
| Q4 25 | $29.1M | $16.3M | ||
| Q3 25 | $38.0M | $-12.4M | ||
| Q2 25 | $71.8M | $33.5M | ||
| Q1 25 | $32.5M | $-16.1M | ||
| Q4 24 | $13.5M | $-10.7M | ||
| Q3 24 | $7.7M | $-35.5M | ||
| Q2 24 | $13.0M | $38.2M | ||
| Q1 24 | $13.7M | $7.0M |
| Q4 25 | 11.8% | 13.1% | ||
| Q3 25 | 16.7% | -14.6% | ||
| Q2 25 | 34.0% | 23.8% | ||
| Q1 25 | 16.5% | -13.9% | ||
| Q4 24 | 7.1% | -8.3% | ||
| Q3 24 | 5.2% | -40.2% | ||
| Q2 24 | 9.4% | 24.0% | ||
| Q1 24 | 10.0% | 5.1% |
| Q4 25 | 0.5% | 8.8% | ||
| Q3 25 | 2.7% | 5.0% | ||
| Q2 25 | 1.9% | 5.2% | ||
| Q1 25 | 1.3% | 5.4% | ||
| Q4 24 | 1.3% | 2.5% | ||
| Q3 24 | 3.2% | 5.3% | ||
| Q2 24 | 3.2% | 3.5% | ||
| Q1 24 | 3.3% | 13.2% |
| Q4 25 | 1.10× | 14.22× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 4.73× | ||
| Q1 25 | 2.23× | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | 1.00× | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SWBI
Segment breakdown not available.
